LONDON, Feb. 17, 2021 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, today announces a research collaboration with Essen University Hospital to examine Theragnostics' investigational agent THG-008 for PET imaging in a range of cancers.